Hu, Y., Li, J., Ni, F. et al. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nat Commun 13, 5313 (2022).
Data Availabilty: https://www.ncbi.nlm.nih.gov/bioproject/PRJNA813944
Jessica R Galloway-Peña, Yushu Shi, Christine B Peterson, Pranoti Sahasrabhojane, Vancheswaran Gopalakrishnan, Chelcy E Brumlow, Naval G Daver, Mansour Alfayez, Prajwal C Boddu, Md Abdul Wadud Khan, Jennifer A Wargo, Kim-Anh Do, Robert R Jenq, Dimitrios P Kontoyiannis, Samuel A Shelburne, Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia, Clinical Infectious Diseases, Volume 71, Issue 1, 1 July 2020, Pages 63–71.
Data Availability: All sequences were deposited in the National Center for Biotechnology Information Sequence Read Archive under the BioProject IDs PRJNA352060 and PRJNA526551.
Rosignoli, C., Petruzzellis, G., Radici, V., Facchin, G., Girgenti, M., Stella, R., Isola, M., Battista, M., Sperotto, A., Geromin, A., Cerno, M., Arzese, A., Deias, P., Tascini, C., Fanin, R., & Patriarca, F. (2020). Risk Factors and Outcome of C. difficileInfection after Hematopoietic Stem Cell Transplantation. Journal of clinical medicine, 9(11), 3673.
retrospective study: 481 patients who underwent autologous (220) or allogeneic HSCT (261) in a 5-year period;overall cumulative incidence of CDI based upon clinical evidence was 5.4% (95% CI, 3.7% to 7.8%); No significant relationship was identified between CDI and the development of acute graft versus host disease (GVHD) after allogeneic HSCT; CDIs were successfully treated with vancomycin or fidaxomicin after auto-HSCT as well as after allo-HSCT.
Paul Feuerstadt, Teena Chopra, Whitfield Knapple, Nicholas W Van Hise, Erik R Dubberke, Brian Baggott, Beth Guthmueller, Lindy Bancke, Michael Gamborg, Theodore S Steiner, Daniel Van Handel, Sahil Khanna, PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection, Clinical Infectious Diseases, Volume 80, Issue 1, 15 January 2025, Pages 43–51